Core Viewpoint - Zai Ding Pharma (ZLAB) has shown a positive market performance with a 2.1% increase in stock price, reaching $34.205 per share, and a total market capitalization of $3.823 billion as of August 21 [1] Financial Performance - As of June 30, 2025, Zai Ding Pharma reported total revenue of $216 million, reflecting a year-on-year growth of 15.35% [1] - The company recorded a net loss attributable to shareholders of $89.165 million, which represents a year-on-year increase of 33.33% [1] Company Overview - Zai Ding Pharma is a patient-centric, innovative global biopharmaceutical company that is in the commercialization stage, focusing on providing optimal and first-in-class drugs for oncology, autoimmune diseases, infectious diseases, and central nervous system disorders [1] - The company's mission is to become a leading global biopharmaceutical company, delivering transformative innovative drugs to patients in China and worldwide [1] - Zai Ding Pharma aims to establish itself as a global leader in biopharmaceuticals, leveraging its base in China to provide innovative therapies for patients globally [1]
再鼎医药上涨2.1%，报34.205美元/股，总市值38.23亿美元